Tolvaptan for treating autosomal dominant polycystic kidney disease

Published on 04 Jun 2024
Last Updated on 04 Jun 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended tolvaptan for inclusion on the MOH List of Subsidised Drugs for treating autosomal dominant polycystic kidney disease (ADPKD). The decision was based on the uncertain extent of clinical benefit, and because tolvaptan was unlikely to represent a cost-effective use of healthcare resources for treating ADPKD.

Tolvaptan for treating autosomal dominant polycystic kidney disease (Published 4 Jun 24) [PDF, 119 KB]

PES Tolvaptan for treating autosomal dominant polycystic kidney disease (Published 4 Jun 24) [PDF, 107 KB]